WO2012074265A2 - Composition pour la promotion de la stabilité des cellules souches - Google Patents

Composition pour la promotion de la stabilité des cellules souches Download PDF

Info

Publication number
WO2012074265A2
WO2012074265A2 PCT/KR2011/009140 KR2011009140W WO2012074265A2 WO 2012074265 A2 WO2012074265 A2 WO 2012074265A2 KR 2011009140 W KR2011009140 W KR 2011009140W WO 2012074265 A2 WO2012074265 A2 WO 2012074265A2
Authority
WO
WIPO (PCT)
Prior art keywords
stem cells
mesenchymal stem
composition
stability
cells
Prior art date
Application number
PCT/KR2011/009140
Other languages
English (en)
Korean (ko)
Other versions
WO2012074265A3 (fr
Inventor
박형근
강성근
라정찬
임자옥
Original Assignee
주식회사 알앤엘바이오
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 알앤엘바이오 filed Critical 주식회사 알앤엘바이오
Publication of WO2012074265A2 publication Critical patent/WO2012074265A2/fr
Publication of WO2012074265A3 publication Critical patent/WO2012074265A3/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells

Definitions

  • the present invention relates to a composition capable of enhancing the stability of stem cells, and more particularly to a composition for enhancing the stability of stem cells containing mesenchymal stem cell culture and base.
  • stem cell research As interest in stem cell research increased, pluripotent stem cells with the ability to form all organs through proliferation and differentiation were found to be able to fundamentally solve long-term damage as well as most diseases. In addition, many scientists have suggested the possibility of applying stem cells to the treatment of almost all organ regeneration of the human body as well as treatment of Parkinson's disease, various cancers, diabetes and spinal cord injury.
  • Stem cells are cells that have the ability to self-replicate and differentiate into two or more cells.
  • Totipotent stem cells pluripotent stem cells, and multipotent stem cells ( multipotent stem cells).
  • Pluripotent stem cells are pluripotent cells that can develop into a complete individual. Cells up to 8-cells after fertilization of eggs and sperm have these properties. Transplantation can result in one complete individual. Pluripotent stem cells are cells that can develop into a variety of cells and tissues derived from ectoderm, mesoderm, and endodermal layer. The inner cell mass inside the blastocyst appears 4-5 days after fertilization. It is called embryonic stem cells and differentiates into a variety of other tissue cells but does not form new life. Multipotent stem cells are stem cells that can only differentiate into cells specific to the tissues and organs that contain them.
  • Multipotent stem cells were first isolated from adult bone marrow (Y. Jiang et al ., Nature , 418: 41, 2002) and subsequently identified in other adult tissues (CM Verfaillie, Trends Cell Biol. , 12: 502, 2002).
  • bone marrow is the most widely known source of stem cells, but multipotent stem cells have also been identified from skin, blood vessels, muscle and brain (JG Toma et al., Nat. Cell Biol ., 3: 778,2001; M Sampaolesi et al ., Science , 301: 487,2003; Y.Jiang et al., Exp. Hematol. , 30: 896,2002).
  • stem cells in adult tissues such as bone marrow are very rare and these cells are difficult to culture without induction of differentiation, making them difficult to culture without specifically screened media. That is, it is very difficult to separate stem cells and preserve them in vitro.
  • adipose tissue is a new source of multipotent stem cells (B. Cousin et al ., BBRC , 301: 1016,2003; A. Miranville et al., Circulation, 110: 349,2004; S. Gronthos et al., J. Cell Physiol ., 189: 54,2001; MJ Seo et al., BBRC , 328: 258,2005).
  • the undifferentiated cell population is included in the human adipose tissue obtained by liposuction (liposuction), and it has the ability to differentiate into adipocytes, bone forming cells, myoblasts and chondrocytes in vitro.
  • liposuction liposuction
  • adipose tissue-derived cells have the ability to promote muscle regeneration and neurovascular differentiation.
  • adipose derived stem cells include human adipose derived adult stem cells capable of differentiation into epithelial cells (M. Brzoska et al ., BBRC , 330: 142,2005), human adipose derived stem stems capable of bone formation and differentiation into adipocytes. Cells (Y. Cao et al ., BBRC , 332: 370,2005), human adipose-derived adult stem cells capable of differentiation into neurons (KM Safford et al., BBRC , 294: 371,2005), capable of differentiating into adipocytes Rat Adipose Stem Cells (R.
  • Rat Adipose Stem Cells capable of Differentiating to Bone Formation and Cartilage Cells R. Ogawa et al., BBRC , 313: 871, 2004
  • human adipose derived stem cells capable of differentiation into chondrocytes HA Awad et al ., Biomaterials , 25: 3211,2004
  • mouse adipose derived stem cells capable of differentiating into neuronal cells J. Fujimura et al., BBRC , 333. : 116,2005) and adipose derived stem cells capable of differentiating into osteoblasts, chondrocytes, neurons or muscle cells (US Pat. No. 6,777, 231).
  • stem cells that can be obtained in large quantities have the potential to be used in the treatment of a wide variety of disorders, including malignant, metabolic congenital abnormalities, hemochromatosis and immunodeficiency.
  • a cell therapy for injecting cells themselves.
  • the survival rate at the time of thawing is not comparable to the refrigeration state, and the survival rate may be slightly increased when the excipient is added, but from a biological point of view, long-term damage to cells and stem cells It may have a low activity potential, which may cause problems, and transportation to a frozen state may be more difficult than refrigerated transportation.
  • a composition for improving stability that maintains the survival rate of stem cells contained in a cell therapy in a refrigerated condition (4 ° C) for a long time stably Development was needed.
  • the present inventors have made intensive efforts to develop a stability enhancing composition for maintaining a high survival rate of stem cells, stem cells when the mesenchymal stem cell culture is added as a composition for improving stability, stem It was confirmed that the survival rate of the cells is maintained stably high for 7 to 10 days, to complete the present invention.
  • An object of the present invention to provide a composition for enhancing the stability of stem cells containing mesenchymal stem cell culture.
  • the present invention (a) K-SFM (Keratinocyte-Serum Free Medium) containing mesenchymal stem cells containing N-Acetyl Cysteine (NAC), ascorbic acid, calcium, insulin and hydrocortisone (Hydrocortisone) Culturing for 4-9 days in medium; And (b) mesenchymal stem cell culture obtained by removing the stem cells cultured in the culture medium; And it provides a composition for enhancing the stability of the stem cells containing the base.
  • K-SFM Keratinocyte-Serum Free Medium
  • the present invention also provides a cell therapy injection product containing the composition for enhancing the stability of the stem cells.
  • 1 is a photograph at 100-fold magnification of cells cultured at 4 ° C. for 3 days.
  • Figure 2 is a graph showing the viability of the cells according to the concentration of the culture at 4 °C.
  • 3 is a photograph at 100-fold magnification of cells cultured at 37 ° C. for 3 days.
  • Figure 4 is a graph showing the viability of the cells according to the concentration of the culture at 37 °C.
  • 5 is a graph showing the viability of the cells cultured in the cell culture medium and 20% culture concentration at 37 °C, respectively.
  • Figure 6 is a graph showing the secretion concentration of procollagen according to the culture time (1 to 9 days) of mesenchymal stem cells.
  • injection cell therapy or cell therapy refers to a defect or in the form of parenteral administration, i.e. injection, containing stem cells to treat a defect in a tissue, thereby correcting the defect. It means a pharmaceutical composition that can be.
  • base refers to a substance added to maintain a form, such as a liquid, in addition to an active ingredient exhibiting pharmacological properties of the pharmaceutical composition, and generally saline as a base for the liquid form.
  • aline Saline
  • Hartmann-D solution PBS (Phosphate Buffered Saline) is used, but it means a substance that can contain various other compositions.
  • stem cell used in the present invention refers to a cell having the ability of self-replicating and differentiating into two or more cells, and "adult stem cell” refers to each organ of the embryo during development. Refers to stem cells appearing in the stage of formation or adulthood.
  • meenchymal stem cell used in the present invention is an undifferentiated stem cell isolated from human or mammalian tissue, and may be derived from various tissues.
  • umbilical cord-derived mesenchymal stem cells umbilical cord blood-derived mesenchymal stem cells, bone marrow-derived mesenchymal stem cells, adipose-derived mesenchymal stem cells, muscle-derived mesenchymal stem cells, nerve-derived mesenchymal stem cells, skin-derived mesenchymal stem cells , Amnion derived mesenchymal stem cells and placental derived mesenchymal stem cells, and techniques for isolating stem cells from each tissue are already known in the art.
  • fat-derived stem cell is an undifferentiated stem cell isolated from adipose tissue, and the separation method may be as follows. In other words, the suspension containing fat suspended in physiological saline obtained from liposuction, and then treated with trypsin of the stem cell layer attached to the culture vessel, such as a flask and recovered or scraped with a scraper to directly float in a small amount of physiological saline. Adipose-derived mesenchymal stem cells can be separated by a method such as recovery.
  • culture liquid used in the present invention means a medium collected after culturing the mesenchymal stem cells in a medium containing a specific component. Eventually, the culture solution contains the cultures (medium components and cell secretions) described below and cultured stem cells.
  • mesenchymal stem cell culture used in the present invention refers to the culture of the mesenchymal stem cells in a medium containing a specific component, the medium is collected, and then the cell debris is removed and the remaining broth ). After all, the culture may be said to contain the secretion of the main components and mesenchymal stem cells contained in the medium.
  • mesenchymal stem cells in a K-SFM (Keratinocyte-Serum Free Medium) medium containing N-Acetyl Cysteine (NAC), ascorbic acid, calcium, insulin, and hydrocortisone (Hydrocortisone) Incubating for 4-9 days;
  • mesenchymal stem cell culture obtained by removing the stem cells cultured in the culture medium; And it relates to a composition for enhancing the stability of stem cells containing the base.
  • the mesenchymal stem cells in the K-SFM medium containing the above components shows a high productivity for various useful components, particularly preferably in the case of culturing for 4 to 9 days . It was confirmed that the secretion concentration of useful components is high. Most preferably, when cultured for 7 to 9 days, the secretion concentration was about 4 times higher than when cultured for 1 to 2 days. When cultured for 9 days or more, it was confirmed that the concentration of the secreted useful components is reduced, and since the culture medium is a serum-free medium, cells are killed by lack of nutrients during long-term culture, which is obvious to those skilled in the art.
  • mesenchymal stem cells in K-SFM Keratinocyte-Serum Free Medium
  • K-SFM Keratinocyte-Serum Free Medium
  • NAC N-Acetyl Cysteine
  • Ascorbic acid calcium
  • insulin and hydrocortisone Hydrocortisone
  • a medium used for obtaining the mesenchymal stem cell culture conventional medium known in the art, which is known to be suitable for stem cell culture, may be used, for example, DMEM, MEM, K-SFM medium, preferably serum free. Medium may be used, and most preferably, K-SFM (Keratinocyte-SFM; Keratinocyte serum free medium) medium may be used.
  • K-SFM Keratinocyte-SFM; Keratinocyte serum free medium
  • the medium used for obtaining the mesenchymal stem cell culture of the present invention contains components such as NAC, ascorbic acid, calcium, insulin and hydrocortisone, and thus the mesenchymal stem cells show high productivity for various useful components.
  • insulin may be included at a concentration of preferably 1-10 ⁇ g / ml.
  • the medium used for obtaining the mesenchymal stem cell culture may be supplemented with additives known in the art, which promote the proliferation of the undifferentiated phenotype of mesenchymal stem cells while inhibiting differentiation.
  • the medium may contain neutral buffers (such as phosphates and / or high concentrations of bicarbonate) and protein nutrients (such as serum, such as FBS, serum substitutes, albumin, or essential and non-essential amino acids, such as glutamine) in isotonic solutions.
  • protein nutrients such as serum, such as FBS, serum substitutes, albumin, or essential and non-essential amino acids, such as glutamine
  • lipids fatty acids, cholesterol, HDL or LDL extracts of serum
  • other components found in most preservative media of this kind such as insulin or transferrin, nucleosides or nucleotides, pyruvate salts, any ionized form or salt
  • Sugar sources such as glucose, selenium, glucocorticoids such as hydrocortisone and / or reducing agents such as ⁇ -mercaptoethanol.
  • the medium also contains anti-clumping agents, such as those sold by Invitrogen (Cat # 0010057AE), with the aim of preventing the cells from adhering to each other, adhering to the vessel wall, or forming too large a bundle. It can be beneficial to do so.
  • anti-clumping agents such as those sold by Invitrogen (Cat # 0010057AE)
  • SCF Stem cell factor
  • Steel factor other ligands or antibodies that dimerize c-kit
  • other active agents of the same signal transduction pathway SCF, Steel factor
  • tyrosine kinase related receptors such as platelet-Derived Growth Factor (PDGF), macrophage colony-stimulating factor, Flt-3 ligand and Vascular Endothelial Growth Factor (VEGF) Ligands for PDGF
  • PDGF platelet-Derived Growth Factor
  • macrophage colony-stimulating factor Flt-3 ligand
  • VEGF Vascular Endothelial Growth Factor
  • Hematopoietic hair growth factors such as thrombopoietin (TPO)
  • Modified growth factors such as TGF ⁇ 1
  • EGF epidermal growth factor
  • Neurotropins such as CNTF
  • N-acetyl-L-cysteine NAC
  • Mesenchymal stem cells for obtaining the mesenchymal stem cell culture of the present invention can be obtained by the following method.
  • the human adipose tissue obtained from the abdomen by liposuction and the like is separated and washed with PBS, and then the tissue is chopped and digested with DMEM medium containing collagen degrading enzyme, followed by washing with PBS and at 1000 rpm. Centrifuge for 5 minutes. The supernatant is removed and the remaining pellets are washed with PBS and centrifuged at 1000 rpm for 5 minutes. The float was removed using a 100 ⁇ m mesh and then washed again with PBS. Incubate in DMEM (10% FBS.
  • mesenchymal stem cells can be separated and passaged to obtain mesenchymal stem cells.
  • mesenchymal stem cells can be obtained by methods known in the art.
  • mesenchymal stem cells can be obtained by methods already known in the art.
  • Mesenchymal stem cells for obtaining the mesenchymal stem cell culture of the present invention can be obtained by the following method.
  • the human adipose tissue obtained from the abdomen by liposuction and the like is separated and washed with PBS, and then the tissue is chopped and digested with DMEM medium containing collagen degrading enzyme, followed by washing with PBS and at 1000 rpm. Centrifuge for 5 minutes. The supernatant is removed and the remaining pellets are washed with PBS and centrifuged at 1000 rpm for 5 minutes. The float was removed using a 100 ⁇ m mesh and then washed again with PBS. Incubate in DMEM (10% FBS.
  • mesenchymal stem cells can be separated and passaged to obtain mesenchymal stem cells.
  • mesenchymal stem cells can be obtained by methods known in the art.
  • mesenchymal stem cells can be obtained by methods already known in the art.
  • Mesenchymal stem cell culture of the present invention can be obtained, for example, by the following method. That is, after culturing the mesenchymal stem cells in 90% confluency, incubated in Keratinocyte-SFM medium containing NAC, ascorbic acid, calcium, insulin and Hydrocortisone for 4-9 days, and then the cells were collected to remove the cells. Mesenchymal stem cell culture can be obtained. Most preferably, the mesenchymal stem cell culture can be obtained by culturing for 7 to 9 days to remove the cell debris by collecting the medium, followed by centrifugation and filtering.
  • the mesenchymal stem cell culture obtained by the above method in a composition for enhancing stability of stem cells 10 to 50% (v / v), preferably 20% (v / v) In this case, it was confirmed that the survival rate of stem cells was significantly higher than that of the conventional one.
  • the mesenchymal stem cell culture may be contained in the composition for enhancing stability of the stem cells preferably 10 to 50% (v / v). More preferably, it may be contained in 10 to 30% (v / v), and most preferably in 20% (v / v).
  • physiological saline As a base contained in the composition for improving stability of the stem cells, physiological saline, Hartmann-D solution, PBS (Phosphate Buffered Saline), which are generally used, may be used.
  • PBS Phosphate Buffered Saline
  • any mechanism used in the art may be used.
  • the mesenchymal stem cell culture obtained by the present invention may contain the following protein components secreted by high concentration of mesenchymal stem cells:
  • TGF-b The transforming growth factor-beta (TGF-b) affects the formation of histogenesis, differentiation and proliferation, cell death, etc. in the embryo, and in the adult, functions such as repairing wound tissue and regulating immune cell proliferation. Do it.
  • IGF-I Insulin-like Growth Factor-1
  • IGF-I is a 7.6kD, single-chain polypeptide hormone formed of 70 amino acids that forms bone, muscle, and nerve tissue in response to growth hormones. It stimulates the differentiation of cells, thereby regenerating damaged cells and promoting growth.
  • HGF hepatocyte growth factor
  • VEGF vascular endothelial growth factor
  • vascular endothelial growth factor is a cytokine that increases the permeation of plasma proteins in capillaries and promotes cell division and migration and induces proteolytic enzymes that cause cell reorganization.
  • VEGF vascular endothelial growth factor
  • the survival of newly formed blood vessels is maintained, and the antigen supply of neurons is suppressed to induce immune regulation to induce cell growth and division. It promotes the migration of vascular cells to promote the development and differentiation of new cells, thereby increasing the composition of the cells.
  • Procollagen is a protein that makes up the dermal layer of the skin and combines with moisture to keep the skin moist and elastic.
  • the mesenchymal stem cells are cord-derived mesenchymal stem cells, umbilical cord blood-derived mesenchymal stem cells, bone marrow-derived mesenchymal stem cells, fat-derived mesenchymal stem cells, muscle-derived mesenchymal stem cells, amniotic membrane-derived mesenchyme It may be a mesenchymal stem cell selected from the group consisting of stem cells and placental derived mesenchymal stem cells.
  • the production of stem cells may be economical fat-derived mesenchymal stem cells.
  • the composition for improving the stability of stem cells if necessary according to the formulation, suspensions, dissolution aids, stabilizers, tonicity agents, preservatives, adsorption inhibitors, surfactants, diluents, excipients, pH adjusters, painless An agent, a buffer, a sulfur-containing reducing agent, an antioxidant, and the like can be appropriately added.
  • suspending agent examples include methyl cellulose, polysorbate 80, hydroxyethyl cellulose, gum arabic, tragantmal, sodium carboxymethyl cellulose, polyoxyethylene sorbitan monolaurate and the like.
  • solution aid examples include polyoxyethylene hardened castor oil, polysorbate 80, nicotinic acid amide, polyoxyethylene sorbitan monolaurate, macrogol, castor oil fatty acid ethyl ester, and the like.
  • Dextran 40 methylcellulose, gelatin, sodium sulfite, sodium metasulfate, etc. are mentioned as a stabilizer.
  • D-mannitol As an isotonic agent, D-mannitol, sorbitol, etc. are mentioned, for example.
  • preservative examples include methyl paraoxybenzoate, ethyl paraoxybenzoate, sorbic acid, phenol, cresol, chlorocresol and the like.
  • adsorption inhibitor examples include human serum albumin, lecithin, dextran, ethylene oxide propylene oxide copolymer, hydroxypropyl cellulose, methyl cellulose, polyoxyethylene hardened castor oil, polyethylene glycol, and the like.
  • sulfur-containing reducing agent examples include N-acetylcysteine, N-acetyl homocysteine, thioctoic acid, thiodiglycol, thioethanolamine, thioglycerol, thiosorbitol, thioglycolic acid and salts thereof, sodium thiosulfate, glutathione and carbon atoms
  • sulfhydryl groups such as thioalkanoic acid of 1-7, etc. are mentioned.
  • antioxidants examples include erythorbic acid, dibutylhydroxytoluene, butylhydroxyanisole, ⁇ -tocopherol, tocopherol acetate, L-ascorbic acid and salts thereof, L-ascorbic acid palmitate, L-ascorbic acid Chelating agents such as stearate, sodium bisulfite, sodium sulfite, triacyl gallate, propyl gallate or sodium ethylenediamine tetraacetate (EDTA), sodium pyrophosphate and sodium metaphosphate.
  • EDTA ethylenediamine tetraacetate
  • the present invention provides a cell therapeutic injection product comprising a composition for enhancing stability of the stem cells.
  • the cell therapy injection product may include a compound generally used for cell therapy, and may also include stem cells, which are the main components of the cell therapy, or adult stem cells, which are sub-populations thereof.
  • the stem cells may be cells passaged or subcultured, preferably stem cells derived from autologous tissue, and most preferably mesenchymal stem cells derived from autologous adipose tissue.
  • Injectables according to the invention can be prepared in the form of filled injections, taking in amounts commonly known in the art, depending on the constitution and type of defect of the patient.
  • Injectable products according to the present invention can be used by injection in a region or a defect adjacent to the defect to be treated, and defects that can be corrected in this way include wrinkles, stretch marks, scars, skin depression, lip dysfunction, periodontal defects, Soft tissue defects, bone defects, burns, skin ulcers, and the like.
  • Adipose tissue was collected from the abdomen through liposuction and washed with PBS. Then, the tissue was chopped and digested at 37 ° C. for 2 hours using DMEM medium containing collagenase type 1 (1 mg / ml). It was. Next, washed with PBS, centrifuged for 5 minutes at 1000 rpm. The supernatant was removed and the remaining pellets at the bottom were washed with PBS and centrifuged at 1000 rpm for 5 minutes.
  • the float was removed using a 100 ⁇ m mesh and then washed again with PBS.
  • the cells were incubated in DMEM (10% FBS, 2 mM NAC, 0.2 mM ascorbic acid), and after overnight, cells not attached to the bottom of the culture vessel were washed with PBS.
  • the keratinocytes-SFM medium containing 2 mM NAC, 0.2 mM ascorbic acid, 0.09 mM calcium, 5 ng / ml rEGF, 50 ⁇ g / ml BPE, 5 ⁇ g / ml insulin and 74 ng / ml hydrocortisone was then added.
  • Multipotent stem cells were isolated by culturing with replacement every two days.
  • Adipose tissue-derived mesenchymal stem cells isolated in Example 1 were cultured at 90% confluency, and then exchanged with keratinocyte-SFM medium containing NAC, ascorbic acid, calcium, insulin and hydrocortisone for 120 hours. .
  • the medium was collected, centrifuged at 1500 rpm for 5 minutes, and cell debris were removed using a 0.22 ⁇ m filter to obtain a mesenchymal stem cell culture.
  • Example 3 Comparative measurement of the survival rate of stem cells according to the culture concentration at 4 °C
  • the mesenchymal stem cell culture obtained according to the method of Example 2 An experiment was performed to compare the survival rate of stem cells suspended in an excipient composition including water and the survival rate of stem cells suspended in a general saline solution.
  • stem cells were prepared by the method of Example 1 to prepare adult stem cells, and washed once with PBS. Thereafter, the mesenchymal stem cell culture of Example 2 was mixed with saline (control; saline 100%), 10%, 20%, 30%, 40%, 50% v / v). The divided vial was prepared at a cell concentration of 2 ⁇ 10 6 cells / 200 ⁇ l per experimental group. This was placed at 4 ° C., the general temperature of the refrigeration agent, and photographed on the third day (FIG. 1), and cell viability was measured at 7 and 10 day intervals.
  • saline control; saline 100%
  • the divided vial was prepared at a cell concentration of 2 ⁇ 10 6 cells / 200 ⁇ l per experimental group. This was placed at 4 ° C., the general temperature of the refrigeration agent, and photographed on the third day (FIG. 1), and cell viability was measured at 7 and 10 day intervals.
  • the preferred concentration of mesenchymal stem cell culture was found to be 10-50%, more preferably 10-30%, and most preferably 20%.
  • Example 4 Measurement of survival rate of stem cells according to the culture concentration at 37 °C
  • the stem cells of Example 1 were prepared and washed once with PBS. Then, the mesenchymal stem cell culture of Example 2 was mixed with saline and divided into a control (saline 100%), 10%, and 20% of 2 x 10 6 cells / 200 ⁇ l of cells per experimental group. Vial was prepared by concentration. This was taken at 37 ° C. to take pictures on day 3 (FIG. 3), and cell viability was measured at 7 and 10 day intervals.
  • Example 5 Measurement of survival rate in the composition for enhancing stability of normal medium and stem cells at 37 ° C
  • the survival rate in the serum-free DMEM medium and the culture-containing composition which is generally used in cell culture, and used as a base for cell therapy for injection, the survival rate was compared by the following method.
  • Example 1 the stem cells of Example 1 were prepared and washed once with PBS. Thereafter, the mesenchymal stem cell culture of Example 2 was mixed with saline to prepare a 20% (v / v) composition, and the same volume of serum-free DMEM cell culture medium was prepared to 2 x per experimental group. Vials were prepared at a cell concentration of 10 6 cells / 200 ⁇ l. Cell viability was measured at 0, 7 and 10 days at 37 degrees Celsius.
  • Cell viability was measured by releasing the cells by tapping the bottom of the vial with a finger to free the sunk cells, diluting them with Trypan blue 1: 1, and measuring the viability using Invitrogen's Countess TM Automated Cell Counter. It was.
  • the culture 20% (v / v) composition according to the present invention shows a survival rate of 83% even on day 10, when using a conventional serum-free cell culture medium, 10 In the first day, only 33%, and confirmed that only 39% survives on the 7th day, it was confirmed the superiority of the composition for enhancing the stability of the stem cells according to the present invention.
  • the components contained in the mesenchymal stem cell culture included in the composition for enhancing the stability of the stem cells of the present invention will contribute to increasing the survival rate of the stem cells included in the cell therapy for injection. Therefore, the concentration of protein components such as TGF, bFGF, IGF, KGF, HGF, Fibronectin, VEGF, and Procollagen will vary depending on the culture time of the mesenchymal stem cells. The secretion concentration of the procollagen was confirmed.
  • Adipose tissue-derived mesenchymal stem cells isolated in Example 1 were incubated in 30 ml of keratinocyte-SFM culture medium containing NAC, ascorbic acid, calcium, insulin and hydrocortisone, and then the medium was collected and centrifuged first. Separation was performed at 1500 rpm for 5 minutes, and secondary cell debris was removed using a 0.22 ⁇ m filter to obtain a mesenchymal stem cell culture. The cultures were then analyzed by ELISA to determine the concentration of procollagen. ELISA analysis was performed using the kit of Table 4 below.
  • the concentration of procollagen identified in the culture at each time point started to increase from 3 days, especially after 4 days, to a concentration above 4000ng / ml which is a preferable concentration. It was confirmed that it was included. The highest concentration of 7995.9 ng / ml was confirmed in the culture of the 8th day, and then lowered again. Therefore, it was confirmed that the time for culturing the mesenchymal stem cells is 4 to 9 days, more preferably 7 to 9 days, most preferably 8 days.
  • the composition for enhancing the stability of the stem cells according to the present invention has the effect of improving the stability of the stem cells and maintaining a high survival rate, and the cells containing the composition for enhancing the stability of the stem cells according to the present invention.
  • the therapeutic injection product can maintain the survival rate of the stem cells contained in the cell therapy for more than 80% for a long time (10 days), so that it can be used for long-term transportation of the cellular therapy injection product, Depending on the survival rate, the effect of the cell therapy is excellent, it can be usefully used for the production of high-quality cell therapy injection products.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une composition qui peut promouvoir la stabilité des cellules souches, et, plus particulièrement, concerne une composition pour la promotion de la stabilité de cellules souches qui contient une culture de cellules souches mésenchymateuses et une base. La composition pour la promotion de la stabilité des cellules souches selon la présente invention présente l'effet avantageux de promouvoir la stabilité des cellules souches et de maintenir un taux élevé de survie, et, dans des produits injectables d'agent thérapeutique cellulaire qui contiennent la composition pour la promotion de la stabilité des cellules souches selon la présente invention, le taux de survie des cellules souches contenues dans l'agent thérapeutique cellulaire peut être maintenu à au moins 80 % pendant une longue durée (10 jours), et, par conséquent, la composition pour la promotion de la stabilité des cellules souches selon la présente invention peut être utilisée dans le transport à longue durée de produits injectables d'agent thérapeutique cellulaire et, en conséquence des taux élevés de survie des cellules souches comprises dans l'agent thérapeutique cellulaire, les avantages en thérapie cellulaire sont remarquables et, par conséquent, l'invention peut également être utilisée de manière avantageuse dans la production de produits injectables d'agent thérapeutique cellulaire de haute qualité.
PCT/KR2011/009140 2010-11-29 2011-11-29 Composition pour la promotion de la stabilité des cellules souches WO2012074265A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020100119284A KR20120057784A (ko) 2010-11-29 2010-11-29 줄기세포의 안정성 증진용 조성물
KR10-2010-0119284 2010-11-29

Publications (2)

Publication Number Publication Date
WO2012074265A2 true WO2012074265A2 (fr) 2012-06-07
WO2012074265A3 WO2012074265A3 (fr) 2012-08-23

Family

ID=46172382

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/009140 WO2012074265A2 (fr) 2010-11-29 2011-11-29 Composition pour la promotion de la stabilité des cellules souches

Country Status (2)

Country Link
KR (1) KR20120057784A (fr)
WO (1) WO2012074265A2 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2811015A1 (fr) * 2011-12-01 2014-12-10 K-Stemcell Co., Ltd. Composition de milieu de culture pour rajeunir des cellules souches
EP2840133A4 (fr) * 2012-04-18 2016-01-06 Jeong Chan Ra Procédé de fabrication de cellule souche ayant une taille adaptée pour l'administration intravasculaire
EP3178318A4 (fr) * 2014-07-08 2017-12-13 Jeong Chan Ra Composition favorisant la stabilité de stockage de cellules souches
US9982234B2 (en) 2013-05-09 2018-05-29 R Bio Co., Ltd Culture medium composition for improving regenerative capacity of stem cells, and stem cell culturing method using same

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101973637B1 (ko) * 2012-06-20 2019-04-30 (주)아모레퍼시픽 진피 유래 성체 줄기세포의 배양방법
WO2019147025A1 (fr) * 2018-01-23 2019-08-01 차의과학대학교 산학협력단 Composition de développement embryonnaire, comprenant un activateur de rad51, et procédé d'amélioration du taux de développement embryonnaire l'utilisant
KR102192587B1 (ko) * 2019-09-30 2020-12-17 대한뉴팜(주) 줄기세포 보관용 부형제 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070119497A (ko) * 2006-06-15 2007-12-20 주식회사 알앤엘바이오 인간 지방조직 유래 다분화능 줄기세포, 섬유아세포 및지방 또는 지방세포를 함유한 피부미용 또는 성형용조성물의 제조방법
KR20080075959A (ko) * 2007-02-14 2008-08-20 (주)프로스테믹스 지방 줄기세포의 조직 재생 능력을 최적화한 배양액을 함유한 조직 재생용 주사제 조성물

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070119497A (ko) * 2006-06-15 2007-12-20 주식회사 알앤엘바이오 인간 지방조직 유래 다분화능 줄기세포, 섬유아세포 및지방 또는 지방세포를 함유한 피부미용 또는 성형용조성물의 제조방법
KR20080075959A (ko) * 2007-02-14 2008-08-20 (주)프로스테믹스 지방 줄기세포의 조직 재생 능력을 최적화한 배양액을 함유한 조직 재생용 주사제 조성물

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NEUPANE ET AL.: 'Isolation and characterization of canine adipose-derived mesenchymal stem cells' TISSUE ENGINEERING vol. 14, no. 6, 2008, pages 1007 - 1015 *
WANG ET AL.: 'Optimizing proliferation and characterization of multipotent stem cells from porcine adipose tissue' BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY vol. 51, 2008, pages 159 - 166 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2811015A1 (fr) * 2011-12-01 2014-12-10 K-Stemcell Co., Ltd. Composition de milieu de culture pour rajeunir des cellules souches
EP2811015A4 (fr) * 2011-12-01 2015-01-21 Stemcell Co Ltd K Composition de milieu de culture pour rajeunir des cellules souches
AU2012346645B2 (en) * 2011-12-01 2015-08-27 R Bio Co., Ltd. Culture-medium composition for rejuvenating stem cells
US9708584B2 (en) 2011-12-01 2017-07-18 R Bio Co., Ltd. Medium composition for rejuvenating stem cells
EP2840133A4 (fr) * 2012-04-18 2016-01-06 Jeong Chan Ra Procédé de fabrication de cellule souche ayant une taille adaptée pour l'administration intravasculaire
US9982234B2 (en) 2013-05-09 2018-05-29 R Bio Co., Ltd Culture medium composition for improving regenerative capacity of stem cells, and stem cell culturing method using same
EP3178318A4 (fr) * 2014-07-08 2017-12-13 Jeong Chan Ra Composition favorisant la stabilité de stockage de cellules souches
US10172347B2 (en) 2014-07-08 2019-01-08 Jeong Chan Ra Composition for improving stability of stem cells

Also Published As

Publication number Publication date
WO2012074265A3 (fr) 2012-08-23
KR20120057784A (ko) 2012-06-07

Similar Documents

Publication Publication Date Title
WO2012074265A2 (fr) Composition pour la promotion de la stabilité des cellules souches
WO2014003319A1 (fr) Procédé de production de cellules souches à haute concentration
AU742638B2 (en) Improved chondrogenic differentiation of human mesenchymal stem cells
US20180171290A1 (en) Method of producing progenitor cells from differentiated cells
WO2013081436A1 (fr) Composition de milieu de culture pour rajeunir des cellules souches
WO2014181954A1 (fr) Composition de milieu de culture pour améliorer la capacité régénérative de cellules souches, et procédé de culture de cellules souches l'utilisant
KR20080081083A (ko) 태반 줄기 세포 집단
WO2013157850A1 (fr) Procédé de fabrication de cellule souche ayant une taille adaptée pour l'administration intravasculaire
WO2013154404A1 (fr) Procédé et composition pour la prévention de la dégradation et de l'agrégation de cellules souches
WO2016006782A1 (fr) Composition favorisant la stabilité de stockage de cellules souches
WO2014185620A1 (fr) Composition de cellules souches pour administration veineuse
WO2019103528A2 (fr) Composition de milieu de culture asérique
WO2024076173A1 (fr) Composition pour induire une différenciation de cellules souches issues du tissu adipeux en cellules de papille dermique, et procédé de différenciation utilisant la composition
WO2013119026A1 (fr) Procédé de différenciation de cellules souches en neurones
WO2021071289A2 (fr) Composition permettant d'augmenter le caractère souche et son utilisation
US20030026786A1 (en) Chondrogenic differentiation of human mesenchymal stem cells
WO2011065661A2 (fr) Procédé de différenciation de cellules souches mésenchymateuses dans des cellules cartilagineuses à l'aide de dkk-1 ou sfrp-1
WO2020004893A1 (fr) Procédé de production de culots de chondrocytes à partir de cellules souches pluripotentes humaines induites, et utilisation associée
KR102281535B1 (ko) 줄기세포 유래 간오가노이드의 제작 및 제１형 혈우병 세포치료제로서의 용도
WO2019221477A1 (fr) Composition pour favoriser la différenciation de cellules souches, comprenant une solution de culture de cellules progénitrices et un film de graphène multicouche, et son utilisation
US20190264174A1 (en) Method of cultivation of human salivary gland cells
WO2017141831A1 (fr) Agent thérapeutique contenant des cellules stromales dérivées de tissu adipeux visant la maladie ischémique, et procédé de production de ce dernier
WO2023090928A1 (fr) Procédé d'isolement, de maintien, de prolifération et de différenciation de cellules monoclonales dérivées de cellules souches épithéliales de glandes salivaires humaines ou de cellules progénitrices et procédé de production de vésicules extracellulaires pour le traitement de maladies des glandes salivaires
EP4209223A1 (fr) Composition pour le traitement de maladies du système nerveux central, procédé de production d'une composition pour le traitement de maladies du système nerveux central et procédé de production d'une formulation thérapeutique pour des maladies du système nerveux central
WO2021125808A1 (fr) Procédé de production de cellules souches présentant une efficacité améliorée

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11845269

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11845269

Country of ref document: EP

Kind code of ref document: A2